1987
DOI: 10.1016/0022-1759(87)90147-5
|View full text |Cite
|
Sign up to set email alerts
|

Hybridoma technology: new developments of practical interest

Abstract: ScopeThis brief review has a limited scope. It focuses on technical developments of practical interest concerning construction of hybridomas and their expansion for large scale production of monoclonal antibodies.Some of the procedures surveyed are not yet routinely applied but are promising. Highlighted are tactics to improve fusion efficiency and production of antibodies in vitro, the use of chemically defined culture media, and attempts at generating antibodies other than murine, especially human.Beginners … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
11
0

Year Published

1988
1988
1994
1994

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 33 publications
(11 citation statements)
references
References 100 publications
0
11
0
Order By: Relevance
“…A large number of methodological variants for the generation of human MAb secreting hybridomas have been reported (2,3,4,8). However, the frequency of their generation as well as their stability have often been reported as poor (3,5).…”
Section: Discussionmentioning
confidence: 98%
See 2 more Smart Citations
“…A large number of methodological variants for the generation of human MAb secreting hybridomas have been reported (2,3,4,8). However, the frequency of their generation as well as their stability have often been reported as poor (3,5).…”
Section: Discussionmentioning
confidence: 98%
“…We tried to generate improved fusion partners and tried to improve the propagation of hybrids. Generally, fusions with human/mouse heteromyelomas are more stable than with xenogeneic mouse myelomas (4,19). However, only about 1% of the total human chromosomal DNA is incorporated in these heteromyeloma cells (13).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…With regard to the current technology to fuse antibody-producing B cells with myeloma partner cells, the most popular technique is polyethylene glycol (PEG)-mediated cell fusion. PEG-fusion gives good yields of hybridomas if carefully controlled by following a detailed procedure, but the uncertainty with respect to the outcome of individual experiments still remains because the success of fusion depends, to some extent, on minute details which are difficult to standardize (1,4). Successful improvements of the fusion technique with electrofusion (2, 3, 4) and immunochemical methods (5, 6) have been reported, but none of these techniques have been widely adopted (1).…”
Section: Introductionmentioning
confidence: 98%
“…PEG-fusion gives good yields of hybridomas if carefully controlled by following a detailed procedure, but the uncertainty with respect to the outcome of individual experiments still remains because the success of fusion depends, to some extent, on minute details which are difficult to standardize (1,4). Successful improvements of the fusion technique with electrofusion (2, 3, 4) and immunochemical methods (5, 6) have been reported, but none of these techniques have been widely adopted (1). Recently reported techniques (7,8) to generate MAbs by use of recombinant DNA methodology show promise, but at present these techniques are still at an experimental stage.…”
Section: Introductionmentioning
confidence: 99%